Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
RELMADA THERAPEUTICS, INC. (RLMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Relmada Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ● NDV-01 CMC program on track to submit the IND by year-end 2026, with initiation of the registrational Phase 3 SPECTRUM program upon IND clearance ● Long-term extension ND
How this was made
The 30-second read
Why it matters
The disclosed Phase 2 durability data and cash position could drive short-term price appreciation, while the upcoming IND submissions present future catalysts.
Market read
First-report earnings and trial data for a clinical-stage biotech, offering fresh material for traders.
What to watch
Potential regulatory delays for IND submission and competition from other NMIBC therapies.
Background
Relmada Therapeutics (Nasdaq: RLMD) released its Q3 2026 financial results and provided an update on its NDV-01 oncology program and sepranolone pipeline.
Ticker impact
Relmada Therapeutics filed its Q3 2026 earnings and disclosed Phase 2 durability data showing 86% of patients remained in complete response at 18 months.
likely upward pressure as investors price in durable responses and extended cash runway
The trial results exceed expectations and the company has sufficient cash to fund operations through 2029, reducing near-term financing risk.
Market effects
Strengthens the oncology biotech sector by showing promising durability in NMIBC therapy.
Minimal regional impact; primarily U.S. biotech investors.
Limited to global biotech investors tracking NMIBC developments.
Counterpoint
The durability data set is small (23 patients) and may not translate to larger Phase 3 outcomes.
Key entities
- ExecutiveSergio Traversa
CEO of Relmada Therapeutics, commented on IND timeline.
- ExecutiveBipin Dalmia
Chief Business Officer, highlighted Phase 2 results.




